Cargando…
Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display
BACKGROUND: There have been significant improvements in Chagas disease therapy and it is now widely accepted that most patients with chronic disease might benefit from therapy. However, there are challenges to monitor drug efficacy and cure for these patients, which are important impediments for cur...
Autores principales: | Rodriguez Carnero, Luis Antonio, Kuramoto, Andréia, Campos de Oliveira, Léa, Monteiro, Jhonatas Sirino, Setubal, João Carlos, Cunha-Neto, Edécio, Cerdeira Sabino, Ester, Giordano, Ricardo José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851536/ https://www.ncbi.nlm.nih.gov/pubmed/36608168 http://dx.doi.org/10.1371/journal.pntd.0011019 |
Ejemplares similares
-
A refined genome phage display methodology delineates the human antibody response in patients with Chagas disease
por: Teixeira, André Azevedo Reis, et al.
Publicado: (2021) -
Protocol for design, construction, and selection of genome phage (gPhage) display libraries
por: Rodriguez Carnero, Luis Antonio, et al.
Publicado: (2021) -
Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018) -
Genome Wide Association Study (GWAS) of Chagas Cardiomyopathy in Trypanosoma cruzi Seropositive Subjects
por: Deng, Xutao, et al.
Publicado: (2013) -
Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)